Jefferies analyst Brian Abrahams kept a Buy rating but lowered his price target on OncoMed Pharmaceuticals (NASDAQ: OMED) to $15.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE